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Abstract
Background: According to the World Health Organization (WHO) the cost of adverse drug reactions (ADRs) in the
general population is high and under-reporting by health professionals is a well-recognized problem. Another way
to increase ADR reporting is to let the consumers themselves report directly to the authorities. In Sweden it is
mandatory for prescribers to report serious ADRs to the Medical Products Agency (MPA), but there are no such
regulations for consumers. The non-profit and independent organization Consumer Association for Medicines and
Health, KILEN has launched the possibility for consumers to report their perceptions and experiences from their use
of medicines in order to strengthen consumer rights within the health care sector. This study aimed to analyze
these consumer reports.
Methods: All reports submitted from January 2002 to April 2009 to an open web site in Sweden where anyone
could report their experience with the use of pharmaceuticals were analyzed with focus on common psychiatric
side effects related to antidepressant usage. More than one ADR for a specific drug could be reported.
Results: In total 665 reports were made during the period. 442 reports concerned antidepressant medications and
the individual antidepressant reports represented 2392 ADRs and 878 (37%) of these were psychiatric ADRs. 75% of
the individual reports concerned serotonin-reuptake inhibitor (SSRI) and the rest serotonin-norepinephrine reuptake
inhibitor (SNRI). Women reported more antidepressant psychiatric ADRs (71%) compared to men (24%). More
potentially serious psychiatric ADRs were frequently reported to KILEN and withdrawal symptoms during
discontinuation were also reported as a common issue.
Conclusions: The present study indicates that consumer reports may contribute with important information
regarding more serious psychiatric ADRs following antidepressant treatment. Consumer reporting may be
considered a complement to traditional ADR reporting.
Background
The World Health Organization (WHO) argues that the
cost of adverse drug reactions (ADRs) in the general
population (in developed countries) is high [1]. Pharma-
coeconomic studies from 1997 and 1998 have estimated
that ADRs may lead to an additional $1.56 to $4 billion
in direct hospital costs per year in the United States
[2-4]. These estimations are however uncertain and in
most countries the extent of this expenditure has not
been measured. The reporting of potential ADRs by
healthcare professionals is supported by WHO and their
Drug Monitoring Programme [5], and under-reporting
by health professionals is a well-recognized problem by
the WHO [6]. Another way to increase ADR reporting
could be to let the consumers themselves report directly
to the authorities.
One important step towards consumer reporting of
ADRs was recently taken by the European Parliament,
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macovigilance legislation to ensure greater patient safety
and to improve public health [7,8]. This was later
cleared by the European Council in December 2010 [9].
The new legislation came into force on 1 January 2011
but will not apply until July 2012 [7,9]. Member States
will then have to adopt these changes in order to har-
monize national adverse event systems, and one impor-
tant change to the current law foresees the inclusion of
direct patient reporting (DPR) of adverse events [10].
Some mean that this will mark the beginning of a new
chapter in drug safety [11]. The WHO acknowledges
that it is not always easy to recognize ADRs (which may
act through the same physiological and pathological
pathways as different diseases) and proposes a step-wise
procedure to assessing possible drug-related ADRs [6].
Therefore, the organization proclaims consumer report-
ing to be of great importance in order to safeguard a
pharmacovigilance that will help each patient to receive
optimum therapy, and on a population basis will lead to
ensure the acceptance and effectiveness of public health
programmes [12].
Consumers in both the Netherlands and Denmark
have had the possibility to report ADRs to their authori-
ties since 2003. Different studies have shown that ADRs
reported by patients has the potential to increase knowl-
edge about the possible harm of medicines [10]. A Dan-
i s hs t u d yo fr e p o r t st ot h eD a n i s hM e d i c i n e sA g e n c y
(DKMA) showed for instance that patients are more
likely to report ADRs from the nervous and psychiatric
system than are health professionals [13]. A Dutch study
indicated that patients seem to report different experi-
ences compared to healthcare professionals regarding
ADRs from antidepressants [14], and that patients now
take great interest in their drug use and often search for
more information about their own medication and often
focus on ADRs [15]. Withdrawal symptoms are accord-
ing to an English study described in a clearer way by
consumer reports compared to how it was done by the
National drug regulatory agencies [16]. However, very
few studies have compared ‘real life’ reports made by
patients and health professionals about antidepressants
[10,14,16,17]. Previous research in the Netherlands and
in Denmark has also suggested that consumer experi-
ences should be included in the evaluation of antide-
pressant treatment in clinical practice [14], and in
systematic drug surveillance systems [13].
In the Nordic countries sales of antidepressants has
increased up to four fold since the middle of the nine-
ties [1], and the sales has now stabilized [18] (Table 1).
In Sweden in 2010 approximately 8.1% of the population
did purchase an antidepressant drug and more than five
million prescriptions of antidepressants were dispensed
to almost 760 000 patients (66% were women) [19]. In
2009 the estimated sales for antidepressants in Sweden
were almost 70 million Euros [20]. Increased use may
be followed by a higher incidence of adverse drug reac-
tions (ADRs) and pharmacovigilance is therefore consid-
ered important aiming to make the best use of
medicines for the treatment or prevention of disease
[12]. In a societal perspective increased knowledge of
this kind is of great importance. In Sweden drug-related
problem may account for as much as 12% of hospital
admissions [21] and the medical burden of fatal ADRs is
estimated to occur in 3% of all deaths [22]. Antidepres-
sants drugs are commonly implicated in FADRs [23].
In Sweden it is mandatory for prescribers to report
potential serious ADRs to the Medical Products Agency
(MPA) [24]. There are however no such regulations for
consumers. Despite the possibility for consumers to report
potential ADRs to the MPA the number of incoming
reports is quite few. The information about how patients
perceive their treatment with antidepressants and their
perception of ADRs is scarce. The non-profit and indepen-
dent organization Consumer Association for Medicines
and Health, KILEN has launched the possibility for consu-
mers to report their perceptions and experiences from
their use of medicines in order to strengthen consumer
rights within the health care sector. KILEN established a
consumer database already in 1997 to collect consumer
reports mainly focusing on benzodiazepines and antide-
pressants. KILEN was created in 1992 but their co-workers
had already a long history of working with pharmaceutical
drug dependency when it in the 1960s became clear that
the new benzodiazepines were causing dependency and
harm. Since 2002 it has also been possible to report
experiences with medicines to KILEN through a web
based report form (http://www.kilen.org). These reports
have not yet been scrutinized and analyzed. Hence, this
study aimed to analyze these consumer reports.
Methods
All reports submitted from January 2002 to April 2009
to KILEN’s internet-based reporting system in Sweden
Table 1 Sales of antidepressants (N06A) in the Nordic
Countries during 1995-2008 in DDD*/1000 inhabitants
per day [1,35]
Denmark Finland Iceland Norway Sweden
1995 18.3 20.3 33.0 22.5 27.8
2000 34.7 35.5 70.5 41.0 48.8
2004 55.2 49.9 91.9 52.4 64.6
2005 59.9 52.1 94.8 51.8 66.1
2006 64.7 55.5 92.6 52.7 69.7
2007 69.9 61.1 95.4 54.8 72.1
2008 73.4 63.9 94.7 55.1 73.7
* Defined Daily Doses according to WHO classification
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ADRs related to antidepressant usage. According to
WHO an ADR is defined as a response to a medicine
which is noxious and unintended, and which occurs at
doses normally used in man whilst an adverse event or
experience is defined as any untoward medical occur-
rence that may present during treatment with a medi-
cine but which does not necessarily have a causal
relationship with this treatment [6].
A report in the KILEN material was defined as one
individual’s reported experience with a drug and an
ADR was equal to one single reported effect connected
to a specific drug. The report form items included user
information (age, sex, location and condition of health),
the story about the treatment (medical history, drugs,
doses and reactions). It was also possible to give a
longer description of the experience as free text. In this
study we chose to analyze age, sex, drug reported and
ADRs. More than ADR related to the same drug could
be submitted. The reported ADRs to KILEN were com-
piled and coded in a similar way to those listed in the
Swedish Physicians’ Desk Reference, FASS. FASS is
building on the Summary of Product Characteristics
(SPC) from the pharmaceutical companies. KILEN per-
sonnel using the database software FileMaker did this
coding.
The drugs in reports were coded according to thera-
peutic groups [Anatomical Therapeutic Chemical (ATC)
system] [25] and types of reported ADRs (system organ
classes) [26]. The ATC Classification with Defined Daily
Doses (ATC/DDD) system classifies therapeutic drugs
and the purpose of the system is to serve as a tool for
drug utilization research in order to improve quality of
drug use [25]. In the ATC classification system, the
drugs are divided into different groups according to the
organ or system on which they act and their chemical,
pharmacological and therapeutic properties [25]. This
system is also valid for the Swedish Physicians’ Desk
Reference, FASS. The ADRs in FASS are classified
according to MedDRA system organ class where reac-
tions are reported corresponding to their frequency
(Very common = >10%, Common = 1-10%, Less com-
mon = 0.1-1%, Rare = 0.01-0.1%, Very rare = <0.01%,
Unknown frequency). Data submitted to KILEN are not
handled to the regulatory authorities like the MPA. The
project was approved by the ethics board in Gothen-
burg, Sweden (No. 319-10).
Results
In total 665 individuals submitted reports on ADRs to a
specific drug and 469 of these concerned antidepres-
sants. Fifteen different antidepressant drugs were
reported but for eight of these antidepressants too little
information (≤10 individual reports) was available. The
442 individual antidepressant reports included in the
study represented 2392 ADRs and of these were 878
psychiatric ADRs (37%) (Table 2). 75% of the individual
reports concerned serotonin-reuptake inhibitor (SSRI)
and 25% a serotonin-norepinephrine reuptake inhibitor
(SNRI). The most reported antidepressants to KILEN
were: Sertraline (26%), Citalopram (24%), Venlafaxine
(18%), Paroxetine (13%), Mirtazapine (8%) Fluoxetine
(6%), and Escitalopram (5%). Sertraline and Citalopram
were the most common antidepressants according to
both reports (116 and 107), total ADRs (626 and 570)
and psychiatric ADRs (226 and 226) (Table 2). Women
were responsible for 323 of the submitted reports com-
pared to men with 98 reports. 21 individuals did not
report their gender and eight individuals did not submit
their age. Of the psychiatric ADRs were women respon-
sible for 622 (70.8%) and men 208 (23.7%), whilst 5.5%
did not report their gender (Table 3). The distribution
of ADRs per report was quite even between women
(5.4) and men (5.2). A majority (34.5%) of the antide-
pressant psychiatric ADRs were reported by consumers
within the age group 30-39 years of age (women 26.8%
and men 6%) (Table 3). Also age groups 15-29 years of
age (23.6%) and 40-49 years of age (22.1%) were com-
mon reporting groups. Several reports to KILEN
included withdrawal symptoms, where one fourth to
one third of psychiatric ADRs were reported during dis-
continuation (Table 4). Women were responsible for a
majority of the reports within the different antidepres-
sants (65.3-82.7%) compared to men (12.2-28.9%) (Table
5 ) .O n l yM i r t a z a p i n ew a sm o r ee v e n l yr e p o r t e d( 5 2 . 1
compared to 43.5%).
The most frequently reported psychiatric ADRs to
KILEN were anxiety, a sensation of unreality, insomnia,
uneasiness/nervousness, irritability, aggressiveness, suici-
dal behavior, and depression (Table 2). The most com-
mon ADR was anxiety (4.2-7.9%). Insomnia was
reported for all antidepressants to KILEN (2.3-6.1%).
The ADR uneasiness/nervousness was reported for five
antidepressants (2.3-2.8%). Experiencing a sensation of
unreality was a common ADR in four analyzed antide-
pressants (2.8-6.2%). Depression was a reported psychia-
tric ADR in three antidepressants (2.1-3.5%). Irritability,
aggressiveness was a reported psychiatric ADR for six
antidepressants (2.1-3.5%). Suicidal behavior was a
reported psychiatric ADR for all antidepressants in the
KILEN material (1.9-3.2).
Discussion
The KILEN material showed reports of potentially ser-
ious psychiatric ADRs. Some psychiatric ADRs were
more reported with certain antidepressants but anxiety,
insomnia and suicidal behavior were reported for all
drugs. But do these consumer reports differ according
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acteristics (SPC)? If we compare reports to KILEN
between the years 2002-2009 with FASS 2004 [27] and
FASS 2009 [28] we take in consideration that it often
takes years before new ADRs are published in FASS.
FASS is the most used tool for health care professionals
in Sweden to use when prescribing drugs and therefore
of interest in a comparison with consumer reports. ADR
information in FASS is mainly based on information
from the pharmaceutical companies and a somewhat
Table 2 Reports and ADRs of antidepressant medication to an open web site according to the system organ class of
psychiatric system
1
Antidepressant ATC code N06A Reports (N)
Total = 442
ADRs (N)
Total = 2392
Psychiatric ADRs (N)
Total = 878
ADRs/report Most common psychiatric ADR (%)
Sertraline
a 116 626 226 5.4 Anxiety 5.9
N06AB06 Sensation of unreality 4.0
Insomnia 3.0
Uneasiness/nervousness 2.6
Irritability, aggressiveness 2.2
Suicidal behavior 1.9
Citalopram
a 107 570 226 5.3 Anxiety 7.9
N06AB04 Insomnia 3.7
Sensation of unreality 2.8
Suicidal behavior 2.5
Uneasiness/nervousness 2.5
Depression 2.1
Irritability, aggressiveness 2.1
Venlafaxine
b 78 505 171 6.5 Anxiety 4.2
N06AX16 Suicidal behavior 3.2
Uneasiness/nervousness 2.8
Sensation of unreality 2.8
Insomnia 2.4
Paroxetine
a 58 327 121 5.6 Anxiety 5.2
N06AB05 Irritability, aggressiveness 3.4
Suicidal behavior 3.1
Insomnia 2.3
Depression 2.1
Mirtazapine
b 34 131 46 3.9 Anxiety 6.9
N06AX11 Insomnia 6.1
Irritability, aggressiveness 3.1
Suicidal behavior 2.3
Uneasiness/nervousness 2.3
Fluoxetine
a 28 120 39 4.3 Anxiety 5.0
N06AB03 Irritability, aggressiveness 2.5
Suicidal behavior 2.5
Insomnia 2.5
Escitalopram
a 21 113 49 5.4 Anxiety 7.1
N06AB10 Sensation of unreality 6.2
Insomnia 5.3
Depression 3.5
Irritability, aggressiveness 3.5
Suicidal behavior 2.7
Uneasiness/nervousness 2.7
1According to ATC classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical,
pharmacological and therapeutic properties.
aSelective serotonin reuptake inhibitor (SSRI)
bSerotonin-norepinephrine reuptake inhibitor (SNRI)
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expected. However, the consumer reports gave another
perspective of experiences with antidepressants. The
consumer reports to KILEN contained more potentially
serious psychiatric ADRs that are not always listed in
FASS, especially experiencing a sensation of unreality,
irritability, aggressiveness, suicidal thoughts, and depres-
sion. Anxiety was the most reported psychiatric ADR to
KILEN for all antidepressants but for some substances
anxiety is not listed at all in one version of FASS, but
listed as common in the other.
This result goes well in accordance with previous
research that consumer/patient reporting does add value
to professional reports of ADRs by identifying possible
new reactions [13,14,29,30]. For instance was a sensation
of unreality an important psychiatric ADR among the
consumer reports to KILEN, but is not listed at all as an
ADR in FASS. Withdrawal symptoms in connection
with discontinuation of antidepressants medication was
reported to KILEN but is not always mentioned in
FASS, and when it is mentioned it is generally regarded
as rare [27,28]. This is worth considering since a study
by Tint and colleagues (2008) showed that withdrawal
symptoms of antidepressants in depressed patients could
be associated with worsening depression symptoms and
increasing suicidal ideation [31].
Consumer reporting may be one way of picking up
harms that are missed in clinical trials, where for
instance the KILEN material introduces a common self
reported harm in experiencing a sensation of unreality.
The new legislation in the EU-countries to stimulate a
systematic consumer reporting can therefore be an
important step to take, and hopefully will also the newly
established consumer reporting system to the Swedish
Medical Product Agency lead to a safer prescription cul-
ture. Since the start in 2008 and up until November
2010 the agency has received over 4000 consumer
reports, according to the MPA. There is however a
major uneven distribution due to the vaccination cam-
paign during the A(H1N1) pandemic in 2009. Research
has also shown that educating general practitioners
(GPs) to focus on ADRs improved the ADR reporting
[32]. This is particularly serious since only five percent
of doctors are estimated to participate in any pharma-
covigilance system [33]. Educating physicians more in
pharmacology or an active involvement of pharmacists
when prescribing medication may therefore be one way
to minimize ADRs and thereby increase safety. Maybe
increased consumer reporting can lead to an increase in
ADR reporting from health professionals. Distribution of
start packages of antidepressant medication can also be
one important aspect in a safer prescription culture and
an important step in minimizing ADRs through better
follow-up. However, as Danish research suggests, can
consumer ADR report might act as whistleblowers of
new and previously undetected ADRs, but if the quality
of the reports is questionable they may bring too much
noise rather than valuable information to the pharma-
covigilance systems [34].
Gender is also an important issue to highlight since
the sales of antidepressants are almost twice as high
among women compared to men in all age groups [35].
Women reported ADRs to KILEN in a much higher
degree, between three to four times more often than
men, and sometimes more within certain age groups.
Especially women 30-39 years of age was a large
Table 3 Consumer reported psychiatric ADRs (N = 878) to KILEN according to age and gender (N) and (%)
Gender Age group
15-29 30-39 40-49 50-59 60-69 70-79 80-89 No age Total
Female 150 (17.1) 235 (26.8) 151 (17.2) 42 (4.8) 17 (1.9) 10 (1.1) - 17 (1.9) 622 (70.8)
Male 46 (5.2) 53 (6.0) 64 (7.3) 30 (3.4) 10 (1.1) - 3 (0.3) 2 (0.2) 208 (23.7)
Not given 9 (1.0) 16 (1.8) 14 (1.6) - - - - 9 (1.0) 48 (5.5)
Total 550 (23.6) 804 (34.5) 515 (22.1) 242 (10.4) 85 (3.6) 23 (1.0) 44 (1.9) 878
Table 4 Reported antidepressant psychiatric ADRs to KILEN during different stages of treatment
Type of reported psychiatric adverse drug reaction and
frequency (N)
During treatment
(%)
During discontinuation treatment
(%)
After treatment
(%)
Anxiety (139) 40 34 26
Sensation of unreality (57) 54 25 21
Insomnia (72) 54 28 18
Uneasiness/nervousness (50) 50 30 20
Irritability/aggressiveness (45) 49 33 18
Suicidal behaviour (59) 68 19 13
Depression (20) 25 45 30
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29 years of age) was a common group. This may be an
effect of that maybe women to a higher degree turn to
non-profit organizations for help. It can also be an effect
of women tending to have a higher risk of ADRs than
men, which increases with age and increased numbers of
drugs prescribed [36]. Citalopram was in particular a
commonly reported antidepressant medication by
women answering for almost 83% of the psychiatric
ADRs for this drug. Both suicidal behavior and depres-
sion, which are more frequently associated with women,
were commonly reported psychiatric ADRs for Citalo-
pram in the KILEN material. There is an almost two-fold
higher occurrence of lifetime prevalence of major depres-
sive disorder and anxiety disorders in females than in
males [37], and older women with a previous history of
treatment by a psychiatrist may have an increased risk of
becoming long-term users of antidepressants [38]. Since
depression was a highly reported psychiatric ADR during
discontinuation in the KILEN material it may be of
importance to include consumer reports when prescrib-
ing the drug of choice for instance depression.
However, this study does have several limitations.
There is for instance the question of potential problems
with polypharmacy, with an unknown interaction
between psychotropic drugs, for instance different anti-
depressants and anxiolytics. As indicated by a Swedish
study the prevalence of polypharmacy, as well as the
mean number of dispensed drugs per individual,
increased for instance year-by-year in Sweden 2005-
2008 [39]. Hence we cannot know for sure if the
reported consumer reports do contain specific psychia-
tric ADRs for one antidepressant drug alone or if it is a
combined effect due to other drugs. Some of the antide-
pressants have quite few reports (Mirtazapine, Fluoxe-
tine and Escitalopram) and therefore it is not possible to
draw any conclusions for each medication. It is a
strength with the KILEN material that consumers are
asked to fill in the report form concerning other medi-
cations as well, but it is still difficult to know if the
reported ADR is a result of a specific medication or the
combination of a number of m e d i c a t i o n s .T h i si sh o w -
ever not unique for KILEN but also valid for the report
form from the MPA. Nevertheless, consumer reporting
may make an important contribution in gaining infor-
mation about unknown drug interactions. The KILEN
data was based on spontaneous consumer reports and
thereby a selected material, which may enhance a
Table 5 Internet reported antidepressant psychiatric ADRs to KILEN according to age and gender (%)
Sertraline Citalopram Venlafaxine Paroxetine Mirtazapine Fluoxetine Escitalopram
Gender
Female 67.3 82.7 68.4 67.8 52.1 71.8 65.3
Male 27.8 16.4 21.6 28.9 43.5 25.6 12.2
Age group
15-29 26.5 12.4 20.5 33.1 37.0 30.8 26.5
Female 16.8 9.7 15.8 24.0 37.0 30.8 10.2
Male 7.1 2.6 4.1 9.1 - - 12.2
30-39 45.5 39.8 27.5 30.6 14.0 17.9 28.6
Female 27.4 36.7 27.5 23.1 - 2.6 28.6
Male 13.3 2.2 - 5.0 14.0 15.4 -
40-49 12.8 27.9 38.6 28.1 4.6 38.5 40.8
Female 11.8 21.2 19.3 13.2 2.3 35.9 24.5
Male 0.9 6.6 15.8 14.9 2.3 2.6 -
50-59 7.5 12.4 5.5 3.3 26.4 2.6 2.0
Female 2.6 8.4 3.6 3.3 11.1 2.6 2.0
Male 4.9 4.0 1.9 - 15.3 - -
60-69 4.9 3.5 - 1.6 14.9 - -
Female 4.0 2.6 - 1.6 - - -
Male 0.9 0.9 - - 14.9 - -
70-79 2.0 - - - - - -
Female 2.0 - - - - - -
Male - - - - - - -
80-89 - - - - - 7.7 -
Female - - - - - - -
Male - - - - - 7.7
No age given 0.8 4.0 7.9 3.9 3.1 2.5 2.1
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these limitations the study is still of value since the
material gives us unique information of consumer
reporting in Sweden.
Conclusions
The present study indicates that consumer reporting
may contribute with important information. Consumer
reporting may be considered a complement to tradi-
tional ADR reporting.
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